3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
31
Neoplasms
8
Endometrial Neoplasms
6
Neoplasm Metastasis
5
Brain Neoplasms
5
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Meningioma
3
Glioblastoma
3
Sarcoma
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Lymphoma, Non-Hodgkin
2
Carcinoma, Non-Small-Cell Lung
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Retinoblastoma
1
Recurrence
1
Pathologic Complete Response
1
Osteosarcoma
1
Neoplasms, Squamous Cell
1
Neoplasm, Residual
1
Multiple Myeloma
1
Interventions
Fluorouracil
37
Radiotherapy
31
Oxaliplatin
29
Cisplatin
28
Paclitaxel
24
Leucovorin
22
Irinotecan
19
Docetaxel
13
pembrolizumab
10
Capecitabine
10
Carboplatin
9
Radiation
8
Neoadjuvant Therapy
8
Cetuximab
8
Surgical Procedures, Operative
7
Folfox protocol
7
Chemotherapy, Adjuvant
6
Nivolumab
5
Gefitinib
5
Taxes
4
Erlotinib Hydrochloride
4
Biopsy
4
durvalumab
3
Panitumumab
3
Itraconazole
3
Epirubicin
3
Bevacizumab
3
tremelimumab
2
spartalizumab
2
ixabepilone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Adenocarcinoma Of Esophagus
×
abemaciclib
×
Clear all
NCT03339843
2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2
Completed
85 enrolled